drugset / Trial / NCT00055887

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00055887 ↗

Phase 3 Withdrawn Spectrum Pharmaceuticals, Inc
RandomizedOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as efaproxiral may make the tumor cells more sensitive to radiation therapy. It is not yet known if chemotherapy combined with radiation therapy is more effective with or without efaproxiral in treating non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy combined with radiation therapy with or without efaproxiral in treating patients who have stage III non-small cell lung cancer.

Timeline

Start
2002-11
Primary completion
—
Completion
—

Outcome

Outcome not reported

Stopped (Enrollment): “Study never started. No patients were enrolled.”

Drugs

EvaluationDrugModalityDoseRoute
Subject efaproxiral Small molecule — Intravenous
Background Carboplatin Small molecule — Intravenous
Background Cisplatin Other / unclassified — Intravenous
Background Gemcitabine Small molecule — Intravenous
Background Paclitaxel Small molecule — Intravenous
Background Vinorelbine Small molecule — Intravenous

Indications